|
Real-time Estimate
Cboe BZX
22:55:30 28/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 6.950 USD | +4.51% |
|
+10.78% | +125.80% |
| 10-25 | Agenus Inc. Reports Early Phase 2 Results From dMMR Colon Cancer Cohort Of NEOASIS Study | CI |
| 10-08 | Agenus Gets Armenia Approval for Botensilimab-Balstilimab Combination | MT |
Company Valuation: Agenus Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 827 | 731.5 | 315.8 | 64.28 | 106.8 | 299.4 | - | - |
| Change | - | -11.54% | -56.83% | -79.65% | 66.13% | 180.36% | - | - |
| Enterprise Value (EV) | 827 | 731.5 | 315.8 | 64.28 | 106.8 | 299.4 | 299.4 | 299.4 |
| Change | - | -11.54% | -56.83% | -79.65% | 66.13% | 180.36% | 0% | 0% |
| P/E | -29.3x | -3.08x | -1.2x | -0.26x | - | 27x | -14x | -14.3x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | -0x | 0.1x | 0x | - | - | 0x | 8.13x |
| Capitalization / Revenue | 2.8x | 7.46x | 2.02x | 0.62x | 0.94x | 2.39x | 2.58x | 2.32x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 2.39x | 2.58x | 2.32x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | 0x | -0x | -0x | -0x | -0x | 5.65x | 11.3x | -78.8x |
| EV / FCF | -0x | -0x | -0x | -0x | -0x | -5.98x | -13.4x | -6.27x |
| FCF Yield | -2.86% | -31.2% | -74.1% | -247% | -72.3% | -16.7% | -7.45% | -15.9% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.2 | -15.6 | -13.8 | -10.59 | - | 0.2467 | -0.4733 | -0.465 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 295.7 | 98.02 | 156.3 | 103.5 | 114.2 | 125.2 | 116 | 129.1 |
| EBITDA | - | -154.1 | - | - | - | - | - | - |
| EBIT 1 | 25.75 | -179.4 | -159.5 | -124.4 | -20.17 | 53 | 26.4 | -3.8 |
| Net income 1 | -24.14 | -230.7 | -257.4 | -232.3 | -0.101 | 39.4 | -28.55 | -53.55 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 64.400 | 48.000 | 16.558 | 2.740 | 3.140 | 6.650 | 6.650 | 6.650 |
| Nbr of stocks (in thousands) | 12,842 | 15,241 | 19,075 | 23,459 | 34,008 | 45,020 | - | - |
| Announcement Date | 01/03/22 | 14/03/23 | 14/03/24 | 11/03/25 | 16/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 26.96x | - | - | - | 299M | |
| 17.08x | 6.33x | 12.4x | 1.75% | 63.48B | |
| 30.03x | 7.96x | 26.08x | 0.05% | 54.55B | |
| 37.03x | 6.57x | 19.63x | 0.87% | 53.59B | |
| 35.05x | 3.37x | 14.55x | -.--% | 44.75B | |
| 48.28x | 5.55x | 30.42x | -.--% | 41.62B | |
| -19.33x | 186.93x | -20.57x | -.--% | 39.91B | |
| 30.28x | 7.94x | 20.6x | 0.4% | 32.47B | |
| 36.51x | 6.64x | 22.27x | -.--% | 26.7B | |
| 26.96x | 5.67x | 14.71x | -.--% | 23.36B | |
| Average | 26.89x | 26.33x | 15.57x | 0.34% | 38.07B | |
| Weighted average by Cap. | 26.55x | 25.23x | 15.68x | 0.46% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- AGEN Stock
- Valuation Agenus Inc.
Select your edition
All financial news and data tailored to specific country editions
